Wuhan Hiteck Biological Pharma Co Ltd (300683) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Wuhan Hiteck Biological Pharma Co Ltd stock ¥16.13, price ¥18.79, that is 14.2% below the price, quality 44 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Wuhan Hiteck Biological Pharma Co Ltd
300683 · SHEExpensive (fair value 14% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ¥18.79 – ¥69.31 · fair‑value band ¥12.10 – ¥20.16 · the ¥18.79 price screens above the ¥16.13 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Wuhan Hiteck Biological Pharma Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.
Show moreShow less
Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection.
The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein.
In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kits for a "Thalassemia.
Further, the company provides Lopinavir and Ritonavir APIs, and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
Stock analysis
Wuhan Hiteck Biological Pharma Co Ltd (300683) currently trades at ¥18.79, while our estimate is ¥16.13, 14% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: ¥12.10 (bear) to ¥20.16 (bull), the price of ¥18.79 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Wuhan Hiteck Biological Pharma Co Ltd reported revenue of 541M CNY in FY2025 versus 615M CNY in FY2021, a compound −3.1%/yr. Reported net income was −231M CNY in FY2025.
Key figures
Market cap 2.5B CNY (≈ $371M) Small · P/S ratio 6.78 · EPS (TTM) ¥-1.47 · Dividend yield 0.6% · Net margin −44.4% · Return on equity −9.1% · Return on assets (EBIT) −2.3% (5-year average) · Operating margin −55.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at −14%, 300683 screens cheaper than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
300683 screens overvalued: fair value 14% below the price. Compare with Merck KGaA →
Compare Wuhan Hiteck Biological Pharma Co Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 611 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Chinese Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $79.11 | $113.53 | +44% | vs 300683 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.00 | ¥51.70 | +10% | vs 300683 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,884.90 | ₹1,982.92 | +5% | vs 300683 |
| Haleon plc HLN | $9.07 | $8.47 | −7% | vs 300683 |
| Merck KGaA MRK | €146.45 | €108.83 | −26% | vs 300683 |
| Galderma Group GALD | CHF 182.85 | CHF 112.84 | −38% | vs 300683 |
| Teva Pharmaceutical Industries Limited TEVA | $39.23 | $20.74 | −47% | vs 300683 |
| Takeda Pharmaceutical Company TAK | $21.77 | $11.26 | −48% | vs 300683 |
| Sandoz Group SDZ | CHF 80.50 | CHF 40.87 | −49% | vs 300683 |
| Divi's Laboratories Limited DIVISLAB | ₹11,180.50 | ₹1,566.89 | −86% | vs 300683 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Wuhan Hiteck Biological Pharma Co Ltd (300683) overvalued or undervalued?
What is the fair value of 300683?
What is the quality score of 300683?
What is the price target for Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the Wuhan Hiteck Biological Pharma Co Ltd stock forecast for 2026?
What is the revenue of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Does Wuhan Hiteck Biological Pharma Co Ltd pay a dividend?
How much is the dividend of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the intrinsic value of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Is Wuhan Hiteck Biological Pharma Co Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 300683?
How much is Wuhan Hiteck Biological Pharma Co Ltd worth?
What do the bullish and bearish scenarios say about 300683?
How solid is the balance sheet of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
How far is 300683 from its 52-week high?
Which stocks are comparable to Wuhan Hiteck Biological Pharma Co Ltd?
Is Wuhan Hiteck Biological Pharma Co Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What should I pay attention to with Wuhan Hiteck Biological Pharma Co Ltd right now?
Key figures of Wuhan Hiteck Biological Pharma Co Ltd
How large is the market capitalisation of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the P/S ratio of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What are the earnings per share of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the dividend yield of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the net margin of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the return on equity of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the EBIT return on assets of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
What is the operating margin of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
How fast is revenue growing at Wuhan Hiteck Biological Pharma Co Ltd (300683)?
How fast are earnings growing at Wuhan Hiteck Biological Pharma Co Ltd (300683)?
How much free cash flow does Wuhan Hiteck Biological Pharma Co Ltd (300683) generate?
How much net cash does Wuhan Hiteck Biological Pharma Co Ltd (300683) hold?
Watch Wuhan Hiteck Biological Pharma Co Ltd in the live analysis
One click puts Wuhan Hiteck Biological Pharma Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.